Company intelligence / Profile preview

Halda Therapeutics

New Haven, Connecticut, United Stateshaldatx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Halda Therapeutics has initiated a Phase 1/2 clinical trial for its lead candidate, HLD-0915, in metastatic castration-resistant prostate cancer (mCRPC). The company's RIPTAC therapeutics are designed to selectively kill cancer cells by inducing proximity between tumor-specific and essential function proteins.

Therapeutic areas: Oncology
Modalities: Small molecules (RIPTAC therapeutics)
Industry: Biotech

Drug pipeline

2 assets

HLD-0915

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Halda Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Halda Therapeutics.

Explore the full profile